ALK EML4-ALK G1269A

EML4-ALK G1269A突变已在对环唑替尼耐药的非小细胞肺癌患者中得到证实。来自多组的细胞系数据表明，这种突变增强了体外对环唑天宁治疗的抵抗力。
The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.

别名

EML4-ALK GLY1269ALA,RS1057519781
Allele Registry ID：CA16602590
ClinVar ID：376132

突变位点

Ref. Build: GRCh37 Ensembl Version: 75

Chr.	Start	Stop	Ref. s	Var. Bases
2	29432682	29432682	C	G
Transcript
ENST00000389048.3

基因序列

ENST00000389048.3:c.3806G>003eC
NC_000002.11:g.29432682C>003eG
NM_004304.4:c.3806G>003eC
NP_004295.2:p.Gly1269Ala